Skip to main content
We are experiencing minor difficulties with our submission forms, which we are working to resolve. If you have any issues while submitting items, please contact us at dspace-lib@mit.edu.
Log in
(current)
MIT Open Scholarship
DSpace@MIT
Search
Home
MIT Open Access Articles
MIT Open Access Articles
Antitumor Antibodies Can Drive Therapeutic T Cell Responses
This is not the latest version of this item. The latest version can be found
here
.
Antitumor Antibodies Can Drive Therapeutic T Cell Responses
Download
Name
nihms892691.pdf
Description
Accepted version
Show more
Size
621.08 KB
Format
Adobe PDF
Checksum
(MD5)
d527230abf728cac567a56d0c5d8d2a5
Show more
sword-2019-09-13T18:23:58.original.xml (130 B)
Original SWORD entry document
Show more
Author(s)
Wittrup, K Dane
Date Issued
2017
Journal
Trends in Cancer
Publisher
Elsevier BV
Version
Author's final manuscript
Abstract
© 2017 Elsevier Inc. The classical view of therapeutic monoclonal antibodies (mAbs) against tumor-associated antigens (TAAs) is that their mechanism of action is dominated by signal blocking or the cytotoxicity of Fc-driven innate immune effector functions. We review here a mounting body of evidence that anti-TAA mAbs are capable of profoundly synergizing with T cell-directed immunotherapies such as checkpoint blockade and adoptive cell therapy. Two key components account for this synergy: (i) a self-vaccinal effect mediated by dendritic cells (DCs); and (ii) an inflammatory repolarization of the tumor microenvironment. Efficient exploitation of these mechanisms has tremendous therapeutic potential.
Show more
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/134531
DOI of Published Version
10.1016/J.TRECAN.2017.07.001
